Duchenne muscular dystrophy (DMD) is a lethal muscle-wasting disease currently without cure. We investigated the use of the PiggyBac transposon for full-length dystrophin expression in murine mesoangioblast (MABs) progenitor cells. DMD murine MABs were transfected with transposable expression vectors for full-length dystrophin and transplanted intra-muscularly or intra-arterially into mdx/SCID mice.
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INTRODUCTION
Duchenne Muscular dystrophy (DMD) is a lethal X-linked muscular dystrophy affecting 1 in 5000 boys.
1,2 DMD results from various types of mutations in the dystrophin gene that lead to progressive muscle wasting, cardiomyopathy and respiratory failure. 3 Despite several research approaches to find a potential cure for the disease, success remains modest. The current palliative care for patients includes the use of anti-inflammatory drugs and corticosteroids, which have been shown to prolong life expectancy to about 30 years of age. 4 Dystrophin provides a physical link between the cytoskeleton of the muscle fiber and the extracellular matrix, and it is required for the assembly and maintenance of the dystroglycan complex. 5 The absence of this protein causes muscle fiber degeneration, inflammation and necrosis, and progressive replacement of muscle with scar and fat tissue. Among the potential treatment strategies that were assessed, exon skipping is one of the most advanced today. 5, 6 Exon-skipping techniques are promising for the treatment of many types of mutations affecting dystrophin, allowing the skipping of single or multiple exons. This method is expected to convert the severe dystrophic phenotype of DMD patients into milder Becker muscular dystrophy-like phenotypes,
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 4
11.1kb open reading frame is required to encode the 427kDa full-length protein, which is difficult to integrate into lenti-and retro-viral gene therapy vectors. Thus, in vivo gene therapy has been attempted using helper-dependent adenoviral vectors that may carry the full-length dystrophin coding sequence, but show limitations with respect to mediating therapeutic dystrophin levels in the entire musculature. Adenoassociated viral (AAV) vectors are another attractive option for efficient systemic delivery in the muscles, however their use is hampered by their restricted packaging capacity. 11 Human artificial chromosome vectors provide another approach towards the expression of the entire dystrophin coding sequence, but face the difficulty of inefficient production and delivery. 12, 13 Gene editing approaches using CRISPR-Cas9 system have also being explored in mouse models, however they cannot be used efficiently to correct large deletions, which form a majority of the mutations in patients, and efficacy on large populations of cultured cells remains limiting. [14] [15] [16] [17] Other pursued alternative approaches consist of the use of truncated versions of the dystrophin sequence encoding micro or minidystrophin proteins, and the up-regulation of utrophin, the homologue of dystrophin. 18, 19, 20, 21, 22 Transposable vectors stably integrate their cargo into permissive regions of the target cell genome, hence enabling long-term expression of the therapeutic genes. 23, 24 For instance, the Sleeping Beauty transposon system has been used for the expression of micro-dystrophin, a shortened version of dystrophin, and dysferlin in muscle dystrophy murine models, and it was optimized for use in a clinical setting.
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expression of full length dystrophin. 28 They combine the easier production of nonviral vectors with efficient transposition and sustained expression in a broad variety of cell types. 29 genomic integration by a cut-and-paste mechanism. 30 Here, we aimed at investigating an autologous cell therapy approach based on fulllength dystrophin expression in mesoangioblasts (MABs), as PB transposon vectors were previously found to yield stable transgene expression in these cells. 28, 31 MABs are progenitor cells associated with blood vessels which are able to differentiate into several mesenchymal tissues, including skeletal muscle. 32 These cells are an attractive option for cell therapy, as they are relatively easy to isolate and culture in vitro, they retain their differentiation properties after culture, they efficiently differentiate into muscle cells in the context of damaged muscle tissues, and they are able to cross blood vessel walls, hence making systemic distribution and migration to regenerating muscle possible. 33, 34 MABs were shown to infiltrate dystrophic muscle from the circulation, engraft into host fibers with high efficiency, and bring along therapeutic genes and proteins. MABs provide such effect either by direct fusion with the muscle fibers or by entering the muscle satellite cell niche. 12, 34 These are promising properties for the systemic and sustained treatment of muscular dystrophies such as DMD.
Given their therapeutic potential to improve muscle structure and function in a large M A N U S C R I P T
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6 animal model, allogeneic MAB transplantation was used in a clinical trial, demonstrating the safety of this approach, however there was no improvement in phenotype after this transplantation. 34, 35 In this study, we wished to establish the use of the native PiggyBac transposon vectors for the expression of full-length dystrophin in MABs, and to assess the therapeutic potential of these MABs following transplantation in the mouse model of DMD. We show that PB-mediated dystrophin coding sequence delivery in mdx mice
MABs, followed by cell transplantation into dystrophic mdx/SCID mice, led to dystrophin expression in mouse muscles and to morphological and functional amelioration of the dystrophic phenotype in mdx/SCID mice.
RESULTS
Characterization of mdx MABs corrected using transposable vectors
The strategy assessed in the present study involved the isolation of MABs from mdx mice and their transfection using the non-viral PiggyBac transposon vectors expressing dystrophin and/or a reporter gene. This was followed by transplantation of the selected myogenic progenitors into dystrophic mouse muscles, and by the characterization of the transplanted cells and muscles for morphological and functional amelioration of the dystrophic phenotype, as summarized in MABs. Transposon integration sites were identified from the sequencing reads spanning both the genome and vector. This approach led to the recovery of 44 distinct integration sites spread over 17 chromosomes of the mouse genome, without a detectable preference for specific chromosomes or genomic loci, as illustrated in Figure 3A . 70% of the integration sites were in intergenic regions, and all integration sites within genes were found to be intronic, none was located in an exon ( Figure   3B ). To investigate if integrations occurred with a preference for upstream regulatory regions such as promoters or enhancers, the occurrence of integration events was plotted relative to the nearest gene sequence and orientation. Most integration sites were scattered beyond 1 kb upstream or downstream of coding sequences, with just 11% of the integrations within 1000bp of a transcription initiation site ( Figure 3B , C). The total number of integration sites per genome was also assessed using qPCR, using both a standard calibration method and comparison to a reference cellular gene for normalization, in addition to whole genome sequencing. These methods revealed between two to six integration events per MAB haploid genome (Supplementary Figure S2D) . Overall, these results were consistent with previous findings that few transposon integration events can lead to sustained transgene expression. 
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Interestingly, the number of dystrophin positive fibers observed after a single transplant remained stable even up to four months after transplantation ( Figure 4D ).
Semi-quantitative analysis of dystrophin signal intensity, as assessed by immunofluorescence and confocal microscopy, revealed that the dystrophin signal intensity of areas with a high proportion of dystrophin-positive myofibers in treated muscles was similar to that of wild type mice muscles (Supplementary Figure S6) . Overall, it was noteworthy that dystrophin expression levels after intramuscular transplantation, were maintained at essentially constant levels at the longest time point assessed, four months after transplantation, and that the dystrophin DNA, RNA levels and number of dystrophin positive fibers in muscles transplanted 3 times was three-fold higher than those of single transplanted muscles. Overall, these data indicated that the genetically modified MABs were able to engraft into murine muscles and to mediate dystrophin expression, which in turn was able to restore the proper localization of the other components of the dystroglycan complex.
Transplanted MABs seed the satellite cell compartment
In order to examine whether transplanted MABs are able to contribute to the muscle satellite cell pool, we transplanted (DYS nlacZ PB) MABs intramuscularly into Figure 5D ). We concluded that the genetically modified MABs could contribute to both differentiating into muscle fibers as well as to replenishing the pool of muscle progenitor cells, in agreement with previous studies. 12 We therefore hypothesized that the MAB-derived satellite-like cells might contribute
dystrophin positive myofibers in a time-sustained fashion, to possibly reduce the progression of the dystrophic disease.
Morphological amelioration of dystrophic muscles after MAB transplantation
To understand whether the restoration of dystrophin expression in the transplanted muscles led to a morphological amelioration of the dystrophic phenotype, fibrotic and 
Functional amelioration of the dystrophic phenotype after MAB transplantation
To investigate whether engraftment and restoration of dystrophin expression was accompanied by improvement in muscle function, we evaluated the functional properties of transplanted muscles. Previous studies indicated that atomic force microscopy (AFM) nano-indentation assays are capable of detecting changes in the resistance to elastic deformation of individual myofibers within muscle explants, as evoked by the presence or absence of dystrophin at the sarcolemmal membrane. 36, 37 M A N U S C R I P T
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Six weeks after a single or three consecutive intramuscular transplantations, myofiber elasticity was probed on longitudinal sections of TA muscles on randomly chosen myofibers at over 100 locations.
The myofiber resistance to elastic deformation was quantified through Young's modulus value (E), which for dystrophin-expressing B6/SCID control muscles was 18.1±9.9 kPa ( Figure 7A ). Figure 7A ). It was possible to infer from this distribution that 80% of the measured fibers had resistance properties similar to healthy muscles, whereas 20% retained the properties of dystrophic myofibers.
Myofibers with a dystrophic or non-dystrophic phenotype were detected as clusters, as was noted for dystrophin expression and for the restoration of dystrophinassociated protein clusters (Supplementary Figure S4, S5 and S7B) . Interestingly, the proportion of myofibers displaying normal elasticity properties was higher than those where dystrophin expression could be detected (80% vs. 45%). This is in agreement with the previous observations that low dystrophin expression levels, which are not easily detected by immunofluorescence, may suffice to restore full myofiber resistance. 38 Thus, immunofluorescence assays likely underestimated the proportion of fibers having elevated dystrophin expression following transplantation.
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To further investigate functional restoration in muscles transplanted 3 times, we performed isometric force measurement on the TA muscles. Tetanic or phasic force parameters were not significantly altered in the transplanted muscles (not shown).
However, MAB transplantation caused a significant restoration of the muscle resistance to fatigue upon repeated tetanic contractions above the untreated mdx/SCID muscles ( Figure 7B-C) . Contraction-induced fatigue, a major cause of weakness of dystrophic muscle, was prevented by more than 60% in muscles injected 3 times with
MABs. Overall, we conclude that the dystroglycan complex and hence the sarcolemmal integrity in the dystrophin-restored regions may be restored in mdx myofibers, conferring the transplanted muscles with physical properties similar to those of wild type muscles and providing an improved resistance to fatigue.
DISCUSSION
Stem cell technologies have the potential to revolutionize medical care as well as provide improved prospects for addressing a host of untreatable muscular dystrophies. 39 The therapeutic potential of muscle stem cells so far has been limited because of their low abundance in adult muscle, and by the fact that in vitro expansion of these cells results in reduced engraftment ability. 40 Also, until now, persistent expression of full-length dystrophin in mouse muscles has been difficult to achieve. 12, 41 It was recently shown that stable transgene expression can be achieved using PiggyBac vectors and MAB transplantation in murine muscles in vivo and that the expression of full-length dystrophin could be mediated by such transposable vectors in vitro. However, whether this may provide a functional amelioration of dystrophic muscles in vivo had not been reported. 28, 31 This study shows that MABs modified with PiggyBac transposon vectors can yield large numbers of dystrophin M A N U S C R I P T
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expressing fibers when transplanted into dystrophic immunodeficient mice, and that this leads to a functional improvement of the transplanted muscles, hence fulfilling some of the criteria required for successful cell therapy of muscular dystrophy. with CRISPR-Cas9, and/or use of a more active transposase. Although we did not M A N U S C R I P T
observe disruption of any exons in this study, nor did we observe any tumorigenesis from the transposon-containing MABs (data not shown), these additional precautions might be needed to further reduce the potential risk of adverse effects due to insertional mutagenesis or mis-regulation of cellular genes.
The levels of dystrophin protein expression achieved in transplanted muscles was 20
to 40% of the wild type levels on a whole-muscle basis. However, positive myofibers of transplanted muscles yielded dystrophin expression up to levels that were comparable to those of wild-type muscles. This was sufficient to ameliorate the dystrophic phenotype, as assessed by histological studies, and to restore normal resistance of most mdx/SCID myofibers in AFM studies. This is consistent with previous studies which reported that even moderate dystrophin expression levels can provide improved muscle structure and function. 12, 14, 15, 17, 45, 38 Such level of dystrophin expression also yielded improved fatigue resistance properties of the treated mdx/SCID muscles.
In clinical protocols, systemic delivery may be imperative for fighting the DMD disease, as intra-muscular delivery would require an excessive number of injections, including in difficult to reach muscles. MABs were previously shown to be able to cross blood vessel walls and to diffuse into-and engraft in-regenerating skeletal muscle when delivered intra-arterially. 12, 33, 34 This study shows that transposoncontaining MABs transplanted into the femoral artery retained ability to migrate across the vessel walls into neighboring muscles where dystrophin-expressing muscle fibers could be detected. However, future studies should seek to further improve the efficiency of IA transplantation, and also to determine if these findings can be extrapolated to human MABs, which have similarities and also some differences relative to their murine counterparts. This engraftment could restore dystrophin and dystroglycan protein complex components, thereby mediating morphological amelioration of the dystrophic phenotype, restoring myofiber stiffness to normal levels and improving the muscle resistance to fatigue.
As of today, exon skipping and premature stop codon read-through are among the most advanced innovative strategies for the treatment of DMD. However, a significant proportion of DMD mutations may not be corrected using these approaches. By contrast, autologous cell transplantation using modified MABs carrying the entire dystrophin cDNA may be a promising therapeutic avenue for the treatment of DMD patients bearing any mutation.
MATERIALS AND METHODS
Animal models and experimentation
All animal experimentations were done in accordance with institutional guidelines and authorizations for animal research by the State of Vaud veterinary office.
Mdx/SCID (B10ScSn.Cg-Prkdc scid Dmd mdx /J) and B6/SCID (B6.CB17-Prkdc scid /SzJ) were purchased from Jackson Laboratory (Jackson, Bar Harbor, ME). They were bred and maintained in a specific pathogen free (SPF) animal facility (University of Lausanne). CD1 nude mice for tumorigenesis assays were purchased from Charles M A N U S C R I P T
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River, France, and housed in an SPF animal facility. Mice were given ad libitum access to food and water, the temperature was maintained at 21°C and humidity at 50-60%. Mice were age, sex and background-matched with their controls for all morphological and functional analysis.
Prior to intra-muscular (IM) transplantation, mice were anesthetized with isoflurane and injected intramuscularly with cardiotoxin (10 µM, 25 µL), so as to induce muscle regeneration. 47 Intra-arterial (IA) transplantations were performed by injecting 500,000 mdx (DYS GFP PB/DYS nlacZ PB) MABs resuspended in 100 µl Ca 2+ and Mg 2+ free PBS into the femoral artery of previously exercised mice (flat treadmill to exhaustion allowing the mice to run till they reach fatigue, a day before injection) so as to induce muscle regeneration and to mimic the more severe condition of human DMD patients. The mice were kept under anesthesia (isofluorane, Attane®), while the artery was isolated and cells were injected into the artery, as previously described.
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Eight to ten week old male mice were used in the study. The total number of grafted mice for single intramuscular transplantations was 20, whereas it was 40 mice for three consecutive intra-muscular transplantations, and 8 mice for intra-arterial transplantations.
Cell culture and plasmids
MABs were isolated from mdx mice as previously described. 46 Briefly, muscles from 7-day old mice were dissected and minced into 1 mm 2 pieces. These pieces were 
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of C2C12 cells to GFP tagged MABs) for seven days in differentiation medium (DMEM supplemented with 2% horse serum (Gibco), 2 mM L-glutamine, 100 IU/mL penicillin and streptomycin). 46 The resulting myofibers were stained for myosinheavy chain MF20 (ThermoFisher, Waltham, MA) to confirm differentiation into myotubes. For promoting the differentiation of MABs into smooth muscle cells, smooth muscle induction medium (DMEM supplemented with 2% horse serum Gibco, 2 mM L-glutamine, 1 mM sodium pyruvate, 100 IU/mL penicillin and 100 µg/mL streptomycin, 5 ng/mL TGFβ1 (Peprotech, Rocky Hill, NJ).
The PiggyBac transposase expression vector has been previously described. 31 Briefly, 
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In vitro cell transmigration assay was performed as previously described. 48 Briefly, mdx (DYS GFP PB) MABs were cultured on a layer of mouse endothelial cells (H5V)
in Transwell ® plate inserts (Corning, Corning, NY). The mdx (DYS GFP PB) MABs migrated on the other side of the filter were counted 11h after seeding (10 random fields at 10x magnification under a fluorescence microscope).
Satellite cell isolation
Satellite cells were isolated from TA muscles of mdx SCID mice transplanted with mdx (DYS GFP PB) MABs 90 days after transplantation, as described previously. Slidescanner VS120-L100).
Cryostat sections were used for hematoxylin and eosin (Sigma) staining, X-gal staining (Invitrogen), Masson trichome staining (Sigma) using standard protocols.
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The slides were then observed under microscopes and images were captured for further analysis (Leica DM5500 / Olympus SlideScanner VS120-L100).
Image analysis was performed using ImageJ software (NIH, Bethesda, MD). For quantification of number of dystrophin positive fibers per muscle cross section, images of the whole cross section were generated using an Olympus SlideScanner This analysis gave an estimate of muscle damage in the treated muscles as compared to the controls.
Tumorigenesis assay
In order to exclude potential tumorigenic mutations due to transposon vector integration events, CD1 nude mice (n=8 per group) were injected subcutaneously in the dorsal flank, with 2,000,000 mdx (DYS GFP PB) MABs resuspended in 100µl of 
PCR and gene copy number assays
DNA from MABs and mouse muscles was purified using the DNeasy Blood & Tissue Kit (Qiagen, Hilden, Germany) as per the manufacturer's instructions. RNA was purified from MABs using NucleoSpin ® RNA kit (Macherey Nagel, Düren, Germany) and from mouse muscles using RNeasy Fibrous Tissue Mini Kit (Qiagen).
cDNA was prepared from 500 ng of each RNA sample using the GoScript™ Reverse Transcription System (Promega, Madison, WI). PCR on mouse muscle genomic DNA, MABs DNA and RT-PCR on mouse cDNA was carried out using Q5 ® HighFidelity DNA Polymerase (New England Biolabs, Ipswich, MA) according to standard protocols. Endpoint PCR analysis was carried out to detect different regions on the human dystrophin coding sequence using primers enlisted as hDYS1, hDYS2
and hDYS3 (Table S1a ). The primers (Microsynth, Baglach, Switzerland) used for the different PCR, quantitative PCR (qPCR) with reverse transcription (RT-qPCR), for transgene copy number or relative RNA level assays, have been listed in Table S1 . Table S1 ).
Genome sequencing and analysis
High molecular weight DNA was isolated from mdx (DYS PB .7-fold from high quality sequences, which was then used to detect dystrophin integration sites mediated by the transposase, as described previously. 53 Integration events were retrieved, using a threshold of more than 10 kb regions of similarity to the transposon sequence, to identify reads spanning both extremities of transposon inserts. At least one of the two transposon borders could be characterized and found to contain the TTAA signature sequence indicative of PB transposition at the junction with the mouse genome, thus confirming that the integration events were transposase mediated.
Western blot
Frozen tissues were prepared and used for immunoblotting as described 
Assessement of muscle function in situ
At the end of the treatment period, the contractile properties of the TA were measured in situ essentially as described elsewhere. 55, 37, 54 In brief, mice were deeply anesthetized, the knee joint was immobilized, the distal tendon of the TA was attached to a force transducer, intramuscular electrodes were inserted, and the tension developed by the TA in response to 0.5 ms-long electrical stimulations was recorded isometrically. The fatigability of the TA exposed to repetitive maximal tetanic contractions was determined: the TA were stimulated at 200 Hz for 200 ms, resulting in fused tetani. A total of 20 tetani were delivered at 30s intervals. The force generated at every tetanus was expressed as the percentage of the initial force. The extent of force loss was calculated from the force remaining at the end of the assay.
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Atomic force microscopy assays
The restoration of the resistance to elastic deformation of individual dystrophinexpressing myofibers was assessed using atomic force microscopy as described previously. 37 After mouse sacrifice, the TA muscles were dissected out and immediately frozen in liquid nitrogen-cooled isopentane and stored at -70C until thawing for use in AFM assays. Before performing measurements, a 1 mm-thick section of the muscle was cut and glued onto a glass coverslip using two 0. 
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This study reports full-length dystrophin expression from PiggyBac transposon vectors transfected in murine mesoangioblast progenitor cells (MAB), as a potential therapeutic autologous cell transplantation approach. Intramuscular MAB transplantation into dmd mice yielded stable dystrophin expression, restored a normal resistance for 80% of the myofibers and increased muscle resistance to fatigue.
